Citigroup upgrades Cynosure CYNO from Buy to Neutral and raises its price target to $22 from $13 on notable improvement reflected in the fourth quarter results.
Citigroup says, "Sales of $34.1MM (+52%) rose 15% on an organic basis and were $2MM ahead of our expectations. R&D (8.3% of sales) and SG&A (43.8% of sales) were a combined $1MM below our forecast and combined with sales led to OP arriving $2MM ahead of our forecast. EPS of $0.11 compared to our estimate of a $0.06 loss and was the first positive quarter since 3Q08. All of the upside came in the North America (NA) laser business which rose 46% on an organic basis."
CYNO closed at $16.44 a share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in